Total Payments
$79,979
2024 Payments
$3,551
Companies
31
Transactions
99
Medicare Patients
3,396
Medicare Billing
$610,773
Payment Breakdown by Category
Consulting$42,204 (52.8%)
Research$14,619 (18.3%)
Travel$11,533 (14.4%)
Other$9,825 (12.3%)
Food & Beverage$1,267 (1.6%)
Education$531.77 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $42,204 | 21 | 52.8% |
| Unspecified | $14,619 | 10 | 18.3% |
| Travel and Lodging | $11,533 | 8 | 14.4% |
| Honoraria | $6,125 | 6 | 7.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,700 | 2 | 4.6% |
| Food and Beverage | $1,267 | 41 | 1.6% |
| Education | $531.77 | 11 | 0.7% |
Payments by Type
General
$65,360
89 transactions
Research
$14,619
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $40,353 | 24 | $0 (2024) |
| Pharmacosmos Therapeutics Inc. | $6,269 | 4 | $0 (2023) |
| AMAG Pharmaceuticals, Inc. | $5,000 | 1 | $0 (2017) |
| Exelixis Inc. | $4,243 | 5 | $0 (2018) |
| Celgene Corporation | $3,125 | 1 | $0 (2017) |
| Athenex Pharmaceutical Division, LLC | $2,647 | 6 | $0 (2021) |
| BeiGene, Ltd. | $2,600 | 1 | $0 (2022) |
| GENZYME CORPORATION | $2,478 | 2 | $0 (2024) |
| Coherus Biosciences Inc. | $2,013 | 1 | $0 (2020) |
| GlaxoSmithKline, LLC. | $1,857 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,551 | 4 | GENZYME CORPORATION ($2,078) |
| 2023 | $6,318 | 6 | Pharmacosmos Therapeutics Inc. ($6,269) |
| 2022 | $11,065 | 7 | Amgen Inc. ($6,610) |
| 2021 | $3,049 | 15 | Amgen Inc. ($883.90) |
| 2020 | $10,633 | 12 | Amgen Inc. ($5,667) |
| 2019 | $5,226 | 14 | Amgen Inc. ($4,400) |
| 2018 | $26,673 | 28 | Amgen Inc. ($19,556) |
| 2017 | $13,465 | 13 | AMAG Pharmaceuticals, Inc. ($5,000) |
All Payment Transactions
99 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,078.00 | General |
| 08/14/2024 | Janssen Scientific Affairs, LLC | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: Oncology | ||||||
| 07/18/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $34.64 | General |
| Category: ONCOLOGY | ||||||
| 01/11/2024 | Amgen Inc. | XGEVA (Biological) | — | In-kind items and services | $1,415.71 | Research |
| Study: Treatment patterns among solid tumor patients with bone metastases: EHR data in US 2013 thru 2017 • Category: Oncology | ||||||
| 04/25/2023 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: HEMATOLOGY | ||||||
| 04/21/2023 | Genentech, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: BioOncology | ||||||
| 03/28/2023 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Travel and Lodging | Cash or cash equivalent | $100.00 | General |
| Category: HEMATOLOGY | ||||||
| 03/07/2023 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Honoraria | Cash or cash equivalent | $3,500.00 | General |
| Category: HEMATOLOGY | ||||||
| 02/27/2023 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Travel and Lodging | In-kind items and services | $419.26 | General |
| Category: HEMATOLOGY | ||||||
| 02/18/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $21.86 | General |
| 12/20/2022 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Oncology | ||||||
| 12/20/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 12/14/2022 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $5,400.00 | General |
| Category: Oncology | ||||||
| 12/14/2022 | Amgen Inc. | XGEVA (Biological) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Oncology | ||||||
| 10/20/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $30.15 | General |
| Category: ONCOLOGY | ||||||
| 10/20/2022 | Genentech, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $25.06 | General |
| Category: BioOncology | ||||||
| 06/01/2022 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $10.28 | General |
| Category: Hematology | ||||||
| 12/20/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $342.50 | General |
| Category: Oncology | ||||||
| 12/20/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Education | In-kind items and services | $48.35 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Education | In-kind items and services | $48.35 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Education | In-kind items and services | $31.28 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Education | In-kind items and services | $31.28 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2021 | Amgen Inc. | XGEVA (Biological) | — | In-kind items and services | $210.25 | Research |
| Study: Identify SRE Risk Factors following XGEVA Discontinuation in Pts with Bone Mets from Solid Tumors • Category: Oncology | ||||||
| 10/06/2021 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Education | In-kind items and services | $16.79 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/29/2021 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Bone-targeted Agent Treatment Patterns and the Impact of Bone Metastases on Patients with Advanced Breast Cancer in the United States | Amgen Inc. | $5,022 | 1 |
| Utilization pattern of GCSF among patients receiving myelosuppressive chemotherapy | Amgen Inc. | $3,781 | 1 |
| Analysis of hospitalizations in cancer patients with chemotherapy in Medicare; 2012-2015 | Amgen Inc. | $1,968 | 2 |
| Treatment patterns among solid tumor patients with bone metastases: EHR data in US 2013 thru 2017 | Amgen Inc. | $1,416 | 1 |
| 1VIT14039 | American Regent | $1,250 | 1 |
| Risk Factors Associated With Skeletal-Related Events Following Denosumab Cessation Among Patients W | Amgen Inc. | $608.85 | 1 |
| NSCLC | Amgen Inc. | $320.24 | 1 |
| Identify SRE Risk Factors following XGEVA Discontinuation in Pts with Bone Mets from Solid Tumors | Amgen Inc. | $210.25 | 1 |
| FN risk reduction with GCSF prophylaxis among breast cancer patients at high FN risk | Amgen Inc. | $42.75 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 722 | 1,329 | $346,500 | $122,542 |
| 2022 | 8 | 746 | 1,387 | $294,521 | $123,610 |
| 2021 | 10 | 839 | 1,603 | $340,135 | $147,871 |
| 2020 | 22 | 1,089 | 16,511 | $644,215 | $216,750 |
Total Patients
3,396
Total Services
20,830
Medicare Billing
$610,773
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 442 | 873 | $194,509 | $72,817 | 37.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 83 | 209 | $68,928 | $25,369 | 36.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 57 | 57 | $27,851 | $8,333 | 29.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 53 | 53 | $18,270 | $5,464 | 29.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 46 | $9,501 | $3,021 | 31.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 29 | $7,880 | $2,751 | 34.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 23 | 35 | $12,460 | $2,615 | 21.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $4,776 | $1,298 | 27.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 14 | 15 | $2,325 | $873.60 | 37.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 421 | 824 | $149,785 | $65,788 | 43.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 63 | 149 | $40,585 | $19,122 | 47.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 128 | 128 | $40,630 | $14,876 | 36.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 40 | 127 | $23,622 | $10,843 | 45.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 38 | 68 | $23,958 | $6,366 | 26.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 51 | $7,191 | $2,917 | 40.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $4,875 | $2,381 | 48.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 23 | 25 | $3,875 | $1,317 | 34.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 415 | 910 | $178,480 | $80,013 | 44.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 59 | 122 | $33,760 | $16,646 | 49.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 65 | 184 | $33,814 | $16,056 | 47.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 89 | 89 | $26,905 | $10,718 | 39.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 39 | 71 | $25,276 | $7,275 | 28.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 34 | 36 | $11,700 | $5,821 | 49.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 52 | 73 | $10,039 | $4,312 | 43.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 28 | 49 | $6,769 | $2,976 | 44.0% |
About Dr. David Henry, MD
Dr. David Henry, MD is a Hematology & Oncology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1063406411.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Henry, MD has received a total of $79,979 in payments from pharmaceutical and medical device companies, with $3,551 received in 2024. These payments were reported across 99 transactions from 31 companies. The most common payment nature is "Consulting Fee" ($42,204).
As a Medicare-enrolled provider, Henry has provided services to 3,396 Medicare beneficiaries, totaling 20,830 services with total Medicare billing of $610,773. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Philadelphia, PA
- Active Since 08/31/2005
- Last Updated 09/09/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1063406411
Products in Payments
- XGEVA (Biological) $13,235
- Aranesp (Biological) $11,448
- Neulasta (Biological) $7,163
- MONOFERRIC (Drug) $6,269
- Prolia (Biological) $5,022
- FERAHEME (Drug) $5,000
- Cabometyx (Drug) $4,243
- Sotatercept (Drug) $3,125
- BRUKINSA (Drug) $2,600
- Oral Paclitaxel (Drug) $2,022
- Udenyca (Biological) $2,013
- i-STAT 1 (Device) $1,725
- Nplate (Biological) $1,660
- IMBRUVICA (Drug) $1,353
- INJECTAFER (Drug) $1,250
- Vitrakvi (Drug) $900.00
- Reblozyl (Drug) $845.00
- ELITEK (Drug) $400.00
- CALQUENCE (Drug) $342.50
- NEUPOGEN (Biological) $278.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Philadelphia
Shayma Kazmi, Md, MD
Hematology & Oncology — Payments: $715,210
Hematology & Oncology $715,210
Charu Aggarwal, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $510,275
Hematology & Oncology $510,275
Dr. Catherine Lai, M.d., M.p.h, M.D., M.P.H
Hematology & Oncology — Payments: $249,951
Hematology & Oncology $249,951
Dr. Martin Edelman, M.d, M.D
Hematology & Oncology — Payments: $207,464
Hematology & Oncology $207,464
Keith Pratz, M.d, M.D
Hematology & Oncology — Payments: $175,955
Hematology & Oncology $175,955
David Porter, Md, MD
Hematology & Oncology — Payments: $173,636
Hematology & Oncology $173,636